Matrix metalloproteinases: Drug targets for myocardial infarction

Andriy Yabluchanskiy, Yaojun Li, Robert J. Chilton, Merry L. Lindsey

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

Original languageEnglish (US)
Pages (from-to)276-286
Number of pages11
JournalCurrent drug targets
Volume14
Issue number3
StatePublished - Apr 30 2013

Fingerprint

Metalloproteases
Matrix Metalloproteinases
Myocardial Infarction
Pharmaceutical Preparations
Ventricular Remodeling
Cell death
Reperfusion
Cell Death
Ischemia
Morbidity
Mortality
Wounds and Injuries
Therapeutics
Research

Keywords

  • Extracellular matrix
  • Left ventricle
  • Left ventricle remodeling
  • Matrix metalloproteinases
  • Myocardial infarction

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Yabluchanskiy, A., Li, Y., Chilton, R. J., & Lindsey, M. L. (2013). Matrix metalloproteinases: Drug targets for myocardial infarction. Current drug targets, 14(3), 276-286.

Matrix metalloproteinases : Drug targets for myocardial infarction. / Yabluchanskiy, Andriy; Li, Yaojun; Chilton, Robert J.; Lindsey, Merry L.

In: Current drug targets, Vol. 14, No. 3, 30.04.2013, p. 276-286.

Research output: Contribution to journalReview article

Yabluchanskiy, A, Li, Y, Chilton, RJ & Lindsey, ML 2013, 'Matrix metalloproteinases: Drug targets for myocardial infarction', Current drug targets, vol. 14, no. 3, pp. 276-286.
Yabluchanskiy A, Li Y, Chilton RJ, Lindsey ML. Matrix metalloproteinases: Drug targets for myocardial infarction. Current drug targets. 2013 Apr 30;14(3):276-286.
Yabluchanskiy, Andriy ; Li, Yaojun ; Chilton, Robert J. ; Lindsey, Merry L. / Matrix metalloproteinases : Drug targets for myocardial infarction. In: Current drug targets. 2013 ; Vol. 14, No. 3. pp. 276-286.
@article{3a17156b5f6544cbb615458a703e1318,
title = "Matrix metalloproteinases: Drug targets for myocardial infarction",
abstract = "Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.",
keywords = "Extracellular matrix, Left ventricle, Left ventricle remodeling, Matrix metalloproteinases, Myocardial infarction",
author = "Andriy Yabluchanskiy and Yaojun Li and Chilton, {Robert J.} and Lindsey, {Merry L.}",
year = "2013",
month = "4",
day = "30",
language = "English (US)",
volume = "14",
pages = "276--286",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Matrix metalloproteinases

T2 - Drug targets for myocardial infarction

AU - Yabluchanskiy, Andriy

AU - Li, Yaojun

AU - Chilton, Robert J.

AU - Lindsey, Merry L.

PY - 2013/4/30

Y1 - 2013/4/30

N2 - Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

AB - Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

KW - Extracellular matrix

KW - Left ventricle

KW - Left ventricle remodeling

KW - Matrix metalloproteinases

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84876739431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876739431&partnerID=8YFLogxK

M3 - Review article

C2 - 23316962

AN - SCOPUS:84876739431

VL - 14

SP - 276

EP - 286

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -